Home > News > BioSante and U.S. Army Co-Developing Ricin Vaccine for Biodefense
February 3rd, 2004
BioSante and U.S. Army Co-Developing Ricin Vaccine for Biodefense
BioSante Pharmaceuticals, Inc. reiterated today its Cooperative Research and Development Agreement with the U.S. Army's Medical Research Institute of Infectious Diseases for the development of a needle-free vaccine against ricin, a poisonous substance thought to have been detected in a U.S. Senate mailroom this week. BioSante has provided BioVant(TM), its proprietary nanoparticulate-based vaccine adjuvant and delivery system, and the Army has provided recombinant antigens to be used in potential vaccines against various bioterrorism agents.
MANA Research Highlight: Smart nanofibers to treat kidney failure March 6th, 2014
Harris & Harris Group, Inc. Establishes and Invests $350,001 in ProMuc, Inc. March 6th, 2014
First Look at How Individual Staphylococcus Cells Adhere to Nanostructures Could Lead to New Ways to Thwart Infections: Berkeley Lab-led research could guide the development of bacteria-resistant materials March 5th, 2014
Dartmouth Researchers Find Promising Results with Local Hyperthermia of Tumors March 4th, 2014